BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/10/2025 7:48:07 AM | Browse: 2 | Download: 1
 |
Received |
|
2025-08-21 05:39 |
|
Peer-Review Started |
|
2025-08-21 05:39 |
|
First Decision by Editorial Office Director |
|
2025-09-25 09:11 |
|
Return for Revision |
|
2025-09-25 09:11 |
|
Revised |
|
2025-10-09 14:45 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-10-31 02:32 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-10-31 07:32 |
|
Articles in Press |
|
2025-10-31 07:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-12-01 07:01 |
|
Publish the Manuscript Online |
|
2025-12-10 07:48 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Levodopa and the dopamine receptor D1-Hippo/yes-associated protein axis: A novel therapeutic avenue for liver fibrosis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Shan-Shan Xie and Zhi-Gang Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Open Project Fund of Henan Provincial Research Center for Precision Diagnosis and Treatment of Pulmonary Diseases Based on Multi-omics |
DZXGCZXKF04 |
|
| Corresponding Author |
Shan-Shan Xie, Professor, /, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, No. 3333 Binsheng Road, Binjiang District, Hangzhou 310052, Zhejiang Province, China. sxie@zju.edu.cn |
| Key Words |
Levodopa; Liver fibrosis; Dopamine receptor D1; Hippo signaling pathway; Yes-associated protein; Drug repurposing; Hepatic stellate cell; G-protein coupled receptor |
| Core Tip |
This editorial highlights a novel mechanistic insight from a recent study by Wang et al, which identifies the dopamine precursor levodopa, a mainstay Parkinson’s disease therapy, as a potent inhibitor of liver fibrosis in experimental models. The antifibrotic effect is mediated through activation of dopamine receptor D1, which stimulates the Hippo signaling pathway to inactivate the profibrotic transcriptional coactivator yes-associated protein. With its decades-long clinical use, safety record, and affordability, levodopa offers translational advantages and positions this neurologic drug as a potentially rapid and cost-effective therapy for chronic liver disease. |
| Publish Date |
2025-12-10 07:48 |
| Citation |
Xie SS, Liu ZG. Levodopa and the dopamine receptor D1-Hippo/yes-associated protein axis: A novel therapeutic avenue for liver fibrosis. World J Gastroenterol 2025; 31(46): 113298 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i46/113298.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i46.113298 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
